查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1269443

放射性医药品治疗诊断市场- 全球产业分析，规模，占有率，成长，趋势，预测，2023-2031年

Radiopharmaceutical Theranostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 226 Pages | 商品交期: 2-10个工作天内

价格

放射性医药品治疗诊断市场- 调查范围:

TMR 的研究报告《全球放射性医药品治疗诊断市场》为了提供2023年～2031年预测期间上关于市场指标的宝贵知识和见解，不仅探讨了过去的增长趋势，还调查了当前的增长趋势和机会。本报告以 2023 年为基准年，2031 年为预测年。提供2017年到2031年的全球放射性医药品治疗诊断市场收益。并刊载2023年2031年的全球放射性医药品治疗诊断市场年复合成长率。

本报告透过广泛研究作成。初步研究中由分析师对主要意见领袖、行业领袖和舆论製造者进行访谈，并进行大部分研究工作。二次研究则参考主要公司的产品资料、年报、新闻稿和相关文件，来掌握放射性医药品治疗诊断市场。

该报告深入探讨全球放射性医药品治疗诊断市场的竞争格局。锁定全球放射性医药品治疗诊断市场活动的主要企业，并对每家公司进行了不同属性的分析。介绍企业概要，财务状况，最近的趋势，SWOT等全球放射性医药品治疗诊断市场企业的属性。

目录

第1章 序文

  • 市场定义和规模
  • 市场区隔
  • 主要的调查目的
  • 调查亮点

第2章 前提条件与调查手法

第3章 摘要整理:全球市场

第4章 市场概要

  • 简介
    • 定义
    • 产业的演进与发展
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球市场的分析与预测，2017-2031年
    • 市场收益预测

第5章 主要洞察

  • 法律规章方案
  • 主要的流通策略
  • 价格设定相关分析
  • 放射性描绘器相关专利
  • 放射性描绘器的技术的进步
  • 放射性描绘器的种类- 概要
  • COVID-19疫情对产业的影响

第6章 全球市场分析·预测:放射性同位元素

  • 简介和定义
  • 主要调查结果/发展情形
  • 市场价值预测:放射性同位元素，2017-2031年
    • Technetium-99
    • 镓-68
    • 碘-131
    • 镭-223
    • 氟-18
    • 钇-90
    • 镏-177
    • 铜-67&64
    • 钐-153
    • 其他
  • 市场魅力分析:放射性同位元素

第7章 全球市场分析·预测:各应用领域

  • 简介&定义
  • 主要调查结果/发展情形
  • 市场价值预测:各应用领域，2017-2031年
    • 肿瘤学
    • 心臟病
    • 其他
  • 市场魅力分析:各应用领域

第8章 全球市场分析·预测:各来源

  • 简介&定义
  • 主要调查结果/发展情形
  • 市场价值预测:各来源，2017-2031年
    • 核子反应炉
    • 迴旋加速器
  • 市场魅力分析:各来源

第9章 全球市场分析·预测:方法

  • 简介和定义
  • 主要调查结果/发展情形
  • 市场价值预测:方法，2017年～2031年
    • 标靶治疗药(Rx)
    • 伴随式诊断药(DX)
  • 市场魅力分析:方法

第10章 全球市场分析·预测:放射性描绘器各类型

  • 简介和定义
  • 主要调查结果/发展情形
  • 市场价值预测:放射性描绘器各类型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市场魅力分析:无线电描绘器各类型

第11章 全球市场分析·预测:各终端用户

  • 简介&定义
  • 主要调查结果/发展情形
  • 市场规模预测:各终端用户，2017年～2031年
    • 医院
    • 学术·研究机关
    • 其他
  • 市场魅力分析:各终端用户

第12章 全球市场分析·预测:各地区

  • 主要调查结果
  • 市场价值预测:各地区，2017-2031年
    • 美国
    • 欧洲
    • 全球其他地区
  • 市场魅力分析:各地区

第13章 美国市场分析·预测

  • 简介
    • 主要调查结果
  • 市场规模预测:放射性同位元素，2017年～2031年
    • Technetium-99
    • 镓-68
    • 碘-131
    • 镭-223
    • 氟-18
    • 钇-90
    • 镏-177
    • 铜-67&64
    • 钐-153
    • 其他
  • 市场价值预测:各应用领域，2017-2031年
    • 肿瘤学
    • 心臟病
    • 其他
  • 市场价值预测:供给来源，2017-2031年
    • 核子反应炉
    • 迴旋加速器
  • 市场价值预测:方法，2017-2031年
    • 标靶治疗药(Rx)
    • 伴随式诊断药(DX)
  • 市场价值预测:放射性描绘器各类型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市场价值预测:各终端用户，2017-2031年
    • 医院
    • 学术·研究机关
    • 其他
  • 市场魅力分析
    • 放射性同位元素
    • 各用途
    • 供给来源
    • 方法
    • 放射性描绘器各类型
    • 各终端用户

第14章 欧洲市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:放射性同位元素，2017-2031年
    • Technetium-99
    • 镓-68
    • 碘-131
    • 镭-223
    • 氟-18
    • 钇-90
    • 镏-177
    • 铜-67&64
    • 钐-153
    • 其他
  • 市场价值预测:各应用领域，2017-2031年
    • 肿瘤学
    • 心臟病
    • 其他
  • 市场价值预测:供给来源，2017-2031年
    • 核子反应炉
    • 迴旋加速器
  • 市场价值预测:方法，2017-2031年
    • 标靶治疗药(Rx)
    • 伴随式诊断药(DX)
  • 市场价值预测:放射性描绘器各类型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市场价值预测:各终端用户，2017-2031年
    • 医院
    • 学术·研究机关
    • 其他
  • 市场价值预测:国家·小各地区，2017-2031年
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲
  • 市场魅力分析
    • 放射性同位元素
    • 各应用领域
    • 各来源
    • 方法
    • 放射性描绘器各类型
    • 各终端用户
    • 各国/辅助region

第15章 全球其他地区的市场分析与预测

  • 简介
    • 主要的调查结果
  • 市场价值预测:放射性同位元素，2017年～2031年
    • Technetium-99
    • 镓-68
    • 碘-131
    • 镭-223
    • 氟-18
    • 钇-90
    • 镏-177
    • 铜-67&64
    • 钐-153
    • 其他
  • 市场价值预测:各应用领域，2017-2031年
    • 肿瘤学
    • 心臟病
    • 其他
  • 市场价值预测:供给来源，2017-2031年
    • 核子反应炉
    • 迴旋加速器
  • 市场价值预测:方法，2017-2031年
    • 标靶治疗药(Rx)
    • 伴随式诊断药(DX)
  • 市场价值预测:放射性描绘器各类型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市场价值预测:各终端用户，2017-2031年
    • 医院
    • 学术·研究机关
    • 其他
  • 市场魅力分析
    • 放射性同位元素
    • 各用途
    • 供给来源
    • 方法
    • 放射性描绘器各类型
    • 各终端用户

第16章 竞争情形

  • 市场竞争矩阵(企业各层级，不同企业规模)
  • 市场占有率分析:各企业(2022年)
  • 企业简介
    • Advanced Accelerator Applications(Novartis AG)
    • Aurobindo Pharma
    • Bayer AG
    • Blue Earth Diagnostics(Bracco)
    • Cardinal Health
    • Clarity Pharmaceuticals
    • GE Healthcare
    • Jubliant Radiopharma
    • Lantheus Medical Imaging
    • Navidea Biopharmaceuticals, Inc.
    • SOFIE
    • Telix Pharmaceuticals
Product Code: TMRGL82604

Radiopharmaceutical Theranostics Market - Scope of Report:

TMR's report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.

The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.

Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report:

  • What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
  • What are the opportunities in the global radiopharmaceutical theranostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Radiopharmaceutical Theranostics Market - Research Objectives and Research Approach:

The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceutical Theranostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario
  • 5.2. Key Distribution Strategies
  • 5.3. Pricing Analysis
  • 5.4. Patents on Radiotracers
  • 5.5. Technological Advancements in Radiopharmaceutical Theranostics
  • 5.6. Radiotracer Type - Overview
  • 5.7. COVID-19 Pandemic Impact on Industry

6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Radioisotope, 2017-2031
    • 6.3.1. Technetium-99
    • 6.3.2. Gallium-68
    • 6.3.3. Iodine-131
    • 6.3.4. Radium-223
    • 6.3.5. Fluorine-18
    • 6.3.6. Yttrium-90
    • 6.3.7. Lutetium-177
    • 6.3.8. Copper-67 & 64
    • 6.3.9. Samarium-153
    • 6.3.10. Others
  • 6.4. Market Attractiveness Analysis, by Radioisotope

7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Oncology
    • 7.3.2. Cardiology
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Source, 2017-2031
    • 8.3.1. Nuclear Reactors
    • 8.3.2. Cyclotrons
  • 8.4. Market Attractiveness Analysis, by Source

9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Approach, 2017-2031
    • 9.3.1. Targeted Therapeutic (Rx)
    • 9.3.2. Companion Diagnostic (DX)
  • 9.4. Market Attractiveness Analysis, by Approach

10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 10.3.1. Peptidic
    • 10.3.2. Non-peptidic
  • 10.4. Market Attractiveness Analysis, by Radiotracer Type

11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user

  • 11.1. Introduction & Definition
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by End-user, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Academic & Research Institutes
    • 11.3.3. Others
  • 11.4. Market Attractiveness Analysis, by End-user

12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2017-2031
    • 12.2.1. U.S.
    • 12.2.2. Europe
    • 12.2.3. Rest of the World
  • 12.3. Market Attractiveness Analysis, by Region

13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 13.2.1. Technetium-99
    • 13.2.2. Gallium-68
    • 13.2.3. Iodine-131
    • 13.2.4. Radium-223
    • 13.2.5. Fluorine-18
    • 13.2.6. Yttrium-90
    • 13.2.7. Lutetium-177
    • 13.2.8. Copper-67 & 64
    • 13.2.9. Samarium-153
    • 13.2.10. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Oncology
    • 13.3.2. Cardiology
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Source, 2017-2031
    • 13.4.1. Nuclear Reactors
    • 13.4.2. Cyclotrons
  • 13.5. Market Value Forecast, by Approach, 2017-2031
    • 13.5.1. Targeted Therapeutic (Rx)
    • 13.5.2. Companion Diagnostic (DX)
  • 13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 13.6.1. Peptidic
    • 13.6.2. Non-peptidic
  • 13.7. Market Value Forecast, by End-user, 2017-2031
    • 13.7.1. Hospitals
    • 13.7.2. Academic & Research Institutes
    • 13.7.3. Others
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Radioisotope
    • 13.8.2. By Application
    • 13.8.3. By Source
    • 13.8.4. By Approach
    • 13.8.5. By Radiotracer Type
    • 13.8.6. By End-user

14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 14.2.1. Technetium-99
    • 14.2.2. Gallium-68
    • 14.2.3. Iodine-131
    • 14.2.4. Radium-223
    • 14.2.5. Fluorine-18
    • 14.2.6. Yttrium-90
    • 14.2.7. Lutetium-177
    • 14.2.8. Copper-67 & 64
    • 14.2.9. Samarium-153
    • 14.2.10. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Oncology
    • 14.3.2. Cardiology
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Source, 2017-2031
    • 14.4.1. Nuclear Reactors
    • 14.4.2. Cyclotrons
  • 14.5. Market Value Forecast, by Approach, 2017-2031
    • 14.5.1. Targeted Therapeutic (Rx)
    • 14.5.2. Companion Diagnostic (DX)
  • 14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 14.6.1. Peptidic
    • 14.6.2. Non-peptidic
  • 14.7. Market Value Forecast, by End-user, 2017-2031
    • 14.7.1. Hospitals
    • 14.7.2. Academic & Research Institutes
    • 14.7.3. Others
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Italy
    • 14.8.5. Spain
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Radioisotope
    • 14.9.2. By Application
    • 14.9.3. By Source
    • 14.9.4. By Approach
    • 14.9.5. By Radiotracer Type
    • 14.9.6. By End-user
    • 14.9.7. By Country/Sub-region

15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 15.2.1. Technetium-99
    • 15.2.2. Gallium-68
    • 15.2.3. Iodine-131
    • 15.2.4. Radium-223
    • 15.2.5. Fluorine-18
    • 15.2.6. Yttrium-90
    • 15.2.7. Lutetium-177
    • 15.2.8. Copper-67 & 64
    • 15.2.9. Samarium-153
    • 15.2.10. Others
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Oncology
    • 15.3.2. Cardiology
    • 15.3.3. Others
  • 15.4. Market Value Forecast, by Source, 2017-2031
    • 15.4.1. Nuclear Reactors
    • 15.4.2. Cyclotrons
  • 15.5. Market Value Forecast, by Approach, 2017-2031
    • 15.5.1. Targeted Therapeutic (Rx)
    • 15.5.2. Companion Diagnostic (DX)
  • 15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 15.6.1. Peptidic
    • 15.6.2. Non-peptidic
  • 15.7. Market Value Forecast, by End-user, 2017-2031
    • 15.7.1. Hospitals
    • 15.7.2. Academic & Research Institutes
    • 15.7.3. Others
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Radioisotope
    • 15.8.2. By Application
    • 15.8.3. By Source
    • 15.8.4. By Approach
    • 15.8.5. By Radiotracer Type
    • 15.8.6. By End-user

16. Competition Landscape

  • 16.1. Market Player Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Advanced Accelerator Applications (Novartis AG)
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Aurobindo Pharma
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bayer AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Blue Earth Diagnostics (Bracco)
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Cardinal Health
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Clarity Pharmaceuticals
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GE Healthcare
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Jubliant Radiopharma
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Lantheus Medical Imaging
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Navidea Biopharmaceuticals, Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. SOFIE
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Telix Pharmaceuticals
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017-2031
  • Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Radiopharmaceutical Theranostics Market Value Share, by Radioisotope, 2022
  • Figure 03: Global Radiopharmaceutical Theranostics Market Value Share, by Application, 2022
  • Figure 04: Global Radiopharmaceutical Theranostics Market Value Share, by Source, 2022
  • Figure 05: Global Radiopharmaceutical Theranostics Market Value Share, by Approach, 2022
  • Figure 06: Global Radiopharmaceutical Theranostics Market Value Share, by End-user, 2022
  • Figure 07: Global Radiopharmaceutical Theranostics Market Value Share, by Radiotracer Type, 2022
  • Figure 08: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 09: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Technetium-99, 2017-2031
  • Figure 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Gallium-68, 2017-2031
  • Figure 12: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-131, 2017-2031
  • Figure 13: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Radium-223, 2017-2031
  • Figure 14: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Fluorine-18, 2017-2031
  • Figure 15: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Yttrium-90, 2017-2031
  • Figure 16: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Lutetium-177, 2017-2031
  • Figure 17: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper-67 & 64, 2017-2031
  • Figure 18: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Samarium-153, 2017-2031
  • Figure 19: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 21: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 22: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Oncology, 2017-2031
  • Figure 23: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cardiology, 2017-2031
  • Figure 24: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 25: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 26: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 27: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Nuclear Reactors, 2017-2031
  • Figure 28: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cyclotrons, 2017-2031
  • Figure 29: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 30: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 31: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Targeted Therapeutic (Rx), 2017-2031
  • Figure 32: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Companion Diagnostic (DX), 2017-2031
  • Figure 33: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 34: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 35: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Peptidic, 2017-2031
  • Figure 36: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Non-peptidic, 2017-2031
  • Figure 37: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 38: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 39: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 40: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 41: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 42: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Region, 2022 and 2031
  • Figure 43: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Region, 2023-2031
  • Figure 44: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 45: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 46: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 47: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 48: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 49: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Source 2022, and 2031
  • Figure 50: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 51: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 52: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 53: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 54: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 55: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 56: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 57: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 58: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 59: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 60: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 61: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 62: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 63: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 64: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 65: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 66: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 67: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 68: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 69: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 70: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 72: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 73: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 74: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 75: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 76: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 77: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 78: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 79: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 80: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 81: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 82: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 83: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 84: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031